Reduced CB1 Cannabinoid Receptor Expression in Alzheimer's Disease and Transgenic Mouse Models

Area of Science:

• Neuroscience
• Pathology
• Pharmacology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline.
• The endocannabinoid system, including the CB1 receptor (CB1R), plays a role in brain function.
• Understanding CB1R's role in AD pathophysiology is crucial for developing new therapeutic strategies.

Purpose of the Study:

• To investigate the expression levels of CB1R in the hippocampus and cortex of AD patients.
• To correlate CB1R expression with neuropathological hallmarks, neuroinflammation, and cognitive status in AD.
• To examine CB1R expression in AD mouse models.

Main Methods:

• Immunohistochemical analysis of post-mortem brain tissue from AD patients and non-demented controls.
• Quantification of CB1R expression and correlation with amyloid-β, tau pathology, GFAP, IBA1, cognitive scores, and ApoE genotype.
• Analysis of CB1R expression in 5xFAD and Tg4-42 AD mouse models.

Main Results:

• Significant reduction in CB1R expression observed in the hippocampus and specific cortical regions of AD patients.
• CB1R levels negatively correlated with amyloid-β and tau pathology.
• CB1R downregulation was consistent in both human AD brains and AD mouse models.

Conclusions:

• Region-specific downregulation of CB1R occurs in Alzheimer's disease.
• CB1R downregulation correlates with key neuropathological features of AD.
• CB1R may represent a potential biomarker or therapeutic target for AD.